CIRM Funded Clinical Trials
TRX103 for prevention of GvHD in patients receiving HLA mismatched HSCT for the treatment of hematologic malignancies
Disease Area:
Immune Disease
Trial Sponsor:
Tr1X Inc.
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
